Intron A (interferon α-2b) / Merck (MSD), Biogen - LARVOL DELTA

U.S. Incidence and Demographics of Ocular Surface Squamous Neoplasia in the IRIS® Registry (Intelligent Research in Sight) 2014-2021. (PubMed, Ophthalmology) - "This is the first study to use the IRIS® Registry as a database for the incidence and demographics of OSSN. Our demographic results are consistent with other studies showing a higher incidence in older, White, and male patients. This study demonstrated that as of 2021 there are at least 2,100 new OSSN cases per year in the U.S and that incidence increased from 2014-2021. The use of the topical immuno-chemotherapy IFN remained a popular treatment modality for OSSN from 2014 through 2021."

Journal • Oncology • Squamous Cell Carcinoma

E3611: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor

E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1673 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • IFNA1

NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Roswell Park Cancer Institute | Suspended ➔ Recruiting | Trial completion date: May 2026 ➔ Nov 2026 | Trial primary completion date: May 2026 ➔ Nov 2026

Biomarker • Enrollment open • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Interferon Alpha Therapy for Cervical CINI and HPV Infection (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Mongolian National University of Medical Sciences | Recruiting ➔ Completed | N=90 ➔ 60 | Trial completion date: Sep 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Nov 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Gynecology • Human Papillomavirus Infection • Infectious Disease

Co-transcriptional splicing is delayed in the highly expressed thyroglobulin gene. (PubMed, J Cell Sci) - "We speculate that this phenomenon is due to the abnormally high transcriptional rate of the Tg gene, which might lead to a localized deficiency in splicing factors and, consequently, delayed spliceosome assembly on thousands of nascent transcripts decorating the gene. Additionally, we found that, in contrast to what is seen for short introns (50 kb) is spliced promptly, providing further support for the idea that intron length might modulate splicing speed."

Journal • TG

Malignant Melanoma of the Tongue: A Systematic Review (EADO-WCM 2025) - "Given the limited evidence base, collaborative efforts among clinicians, pathologists, and oncologists are vital to advancing diagnostic and therapeutic approaches. Future research focusing on larger case series, genetic pathways, and novel therapies is needed to bridge current knowledge gaps and improve outcomes for this rare and aggressive malignancy."

IO biomarker • Review • Melanoma • Oncology • Solid Tumor

SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov) - P3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Endocrine Cancer • Gastric Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma

Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs (CROI 2025) - P1 | "Participants in the NCT03588715 (BEAT2) clinical trial received six infusions of the bNAbs 3BNC117 and 10-1074, and thirty doses of IFNa2b...Higher proportions of replication-competent outgrowth viruses neutralized by aNAbs was associated with a more delayed time-to-rebound following cessation of all immunotherapies. ATI studies must consider the role of pre-existing aNAbs in potentially confounding time-to-rebound measurements."

IO biomarker • Human Immunodeficiency Virus • Infectious Disease • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1301 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

Hypoxia-induced ATF3 escalates breast cancer invasion by increasing collagen deposition via P4HA1. (PubMed, Cell Death Dis) - "These results reveal a novel hypoxia-induced HIF1ɑ-ATF3-P4HA1 axis which can potentially be exploited as a therapeutic target to impede EMT and ultimately breast cancer invasion. Hypoxia induced ATF3 regulates P4HA1 expression and alternative splicing to promote breast cancer invasion."

Journal • Breast Cancer • Oncology • Solid Tumor • ATF3 • HIF1A • P4HA1

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Nov 2025 ➔ Nov 2027 | Trial primary completion date: Nov 2025 ➔ Nov 2027

IO biomarker • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • CD8

A exploratory study to evaluate the efficacy and safety of interferon-α combined with ATO in the treatment of arsenic-resistant acute promyelocytic leukemia (ChiCTR) - P=N/A | N=15 | Not yet recruiting | Sponsor: Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital

New trial • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • PML

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (clinicaltrials.gov) - P3 | N=586 | Recruiting | Sponsor: University of Birmingham | Trial completion date: Feb 2028 ➔ Apr 2030 | Trial primary completion date: Aug 2026 ➔ Oct 2028

Trial completion date • Trial primary completion date • Polycythemia Vera

A Scoping Review of Arthropod-Borne Flavivirus Infections in Solid Organ Transplant Recipients. (PubMed, Transpl Infect Dis) - "Treatment involved reducing immunosuppression (IS) in 93 cases, with intravenous immunoglobulin (IVIG), interferon alfa-2b, and ribavirin used in 75 cases...Additionally, 26 cases of less common ABFs such as JEV, POWV, YFV, and ZIKV were described. In summary, ABF infections among SOTRs are associated with higher morbidity and mortality compared to the general population, emphasizing the need for improved preventive strategies, timely diagnosis, and optimized management protocols."

Journal • Review • CNS Disorders • Dengue Fever • Infectious Disease • Musculoskeletal Pain • Pain • Solid Organ Transplantation • Transplantation

Commitment Complex Splicing Factors in Cancers of the Gastrointestinal Tract-An In Silico Study. (PubMed, Bioinform Biol Insights) - "This study demonstrates the versatility of in silico analysis to determine molecular function of large macromolecular complexes such as the spliceosome CC. Furthermore, our analysis indicates that therapeutic lowering of CC levels in colon cancer patients may enhance patient survival."

Journal • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Pancreatic Cancer • Solid Tumor • BRAF • KRAS • TP53 • U2AF1

A 34-year retrospective study of skin adnexal tumors in a tertiary hospital in Southern Taiwan (EADV 2024) - "For malignant skin adnexal tumors, surgery is typically the mainstay of treatment, with radiotherapy, chemotherapy and photodynamic therapy reserved for adjuvant, palliative, and re-treatment scenarios."

Retrospective data • Atopic Dermatitis • Dermatology • Immunology • Infectious Disease • Oncology • Rare Diseases • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

The Arabidopsis U1 snRNP regulates mRNA 3'-end processing. (PubMed, Nat Plants) - "Interestingly, we found that the U1 snRNP protects mRNAs against premature cleavage and polyadenylation within introns-a mechanism known as telescripting in metazoans-while also influencing alternative polyadenylation site selection in 3'-UTRs. Overall, our work provides a comprehensive view of U1 snRNP interactors and reveals novel functions in regulating mRNA 3'-end processing in Arabidopsis, laying the groundwork for understanding non-canonical functions of plant U1 snRNPs."

Journal

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Aug 2025 ➔ Nov 2025 | Trial primary completion date: Aug 2025 ➔ Nov 2025

Combination therapy • IO biomarker • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • CD8

Integrated analysis reveals the immunotoxicity mechanism of BPs on human lymphocytes. (PubMed, Chem Biol Interact) - "In addition, the results of ingenuity pathway analysis demonstrated the inhibition of T lymphocyte function, including differentiation, movement, and infiltration. Our results, for the first time, delineate the mechanisms underlying the immunotoxicity of BHPF in human lymphocytes."

Journal • Oncology • CXCL8 • IL1B • IL5 • IL6 • TNFA

NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov) - P2 | N=30 | Suspended | Sponsor: Roswell Park Cancer Institute | Trial completion date: May 2024 ➔ May 2026 | Trial primary completion date: May 2024 ➔ May 2026

Biomarker • Surgery • Trial completion date • Trial primary completion date • Tumor microenvironment • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Case report: Clinical features and management outcomes of isolated corneal intraepithelial neoplasia. (PubMed, Front Ophthalmol (Lausanne)) - "Case 1 was a 45-year-old male who presented with an isolated grayish amoeboid corneal lesion which was excised with alcohol assisted epitheliectomy, he also received 6 cycles of topical mitomycin C (MMC) 0.02% and one injection of interferon alfa-2b with no recurrence during the 10-year follow-up period...Case 3 was a 63-year-old male patient who presented with an isolated corneal lesion that was excised using alcohol-assisted epitheliectomy, patient received four cycles of topical 5-fluorouracil with no recurrence at last follow-up visit at 6 months. Isolated corneal intraepithelial neoplasia (CIN) is a rare entity with few reported cases in the literature. In this case series, we report long and short-term management outcomes of combined surgical and medical therapy for isolated CIN."

Journal • Oncology • Squamous Cell Carcinoma

Polymorphisms of cell cycle regulators: risk factor for prostate cancer (EACR 2024) - "After analysis of the associations of clinical status, the p21 polymorphism showed a positive association with a higher Gleason score (>7) (p=0,005). No significant associations were found for the CDK1 but we found out for the combined genotypes of CDK1 (AA) and p21 (GC) significantly increase the risk of PCa compared to individuals with wild-type genotypes (p=0,05).Conclusion We assume that this finding of single nucleotide polymorphisms could be one of the genetic markers of prostate cancer."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CDK1 • CDKN1A

Cost effectiveness analysis of nadofaragene firadenovec for the treatment of high-risk, bacillus Calmette-Guerin–unresponsive, non-muscle invasive bladder cancer from a US third-party payer perspective. (ASCO 2024) - P2, P3 | "The analysis suggests that nadofaragene firadenovec is cost-effective compared to pembrolizumab for the treatment of high-risk, BCG unresponsive NMIBC with CIS ± Ta/T1 at a willingness to pay of $150,000/QALY."

Cost effectiveness • HEOR • Bladder Cancer • Gene Therapies • Genito-urinary Cancer • Oncology • Solid Tumor

Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404. (ASCO 2024) - P3 | " This study included 92 pts with resected stage III melanoma enrolled in a phase 3 trial (NCT02506153) that evaluated the efficacy of adjuvant pembrolizumab compared to interferon alfa-2b or ipilimumab in pts with stage IIIA(N2a)-IV resected melanoma... In this study, pre-Tx incidence of ctDNA+ after surgical resection was low, potentially related to limited plasma yield. However, the ctDNA positivity rate increased in subsequent serial testing. ctDNA might help identify early disease recurrence in patients with melanoma in the adjuvant setting, but further studies of larger cohorts accounting for treatment effect with more uniform pre-analytic collection are needed."

Circulating tumor DNA • Clinical • Melanoma • Oncology • Solid Tumor • BRAF